You are in:Home/Publications/Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome

Dr. Khalid abd elaziz Mohamed Ibrahem :: Publications:

Title:
Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome
Authors: Ahmed Samy Saad a,b,⇑, Khalid Abd Aziz Mohamed a
Year: 2017
Keywords: Not Available
Journal: Middle East Fertility Society Journa
Volume: 22
Issue: Not Available
Pages: 206-210
Publisher: ScienceDirect
Local/International: International
Paper Link:
Full paper Khalid abd elaziz Mohamed Ibrahem_Diosmin versus cabergoline..pdf
Supplementary materials Not Available
Abstract:

Background: OHSS (Ovarian Hyperstimulation Syndrome) is the most serious iatrogenic complication of ovulation induction. The pathophysiology of OHSS is characterised by increased capillary permeability, leading to leakage of fluid from the vascular compartment, with third space fluid accumulation and intravascular dehydration. Objective: This study aimed to evaluate the effectiveness of diosmin in comparison to the dopamine ago- nist cabergoline in preventing OHSS in high risk patients undergoing assisted reproductive technique cycles. Methods: In this study, 200 women who were at high risk for developing OHSS were randomly allocated into two groups. Group A (Diosmin group, 100 women) and group B (Cabergoline group, 100 women). All patients were assessed every two weeks after retrieval and for 8 weeks to determine early clinical or ultrasound evidence of OHSS. Results: There was a statistically significant reduction (P = 0.005) in the incidence of OHSS in the diosmin group (12%) compared to cabergoline group (28%). The number of severe OHSS cases in the cabergoline group (n = 13) was significantly higher (P = 0.003) than the diosmin group (n = 2). There was no differ- ence in clinical pregnancy rate. Conclusion: Our results concluded that diosmin was more effective in preventing severe OHSS and decreasing OHSS occurrence rates than cabergoline when used in high-risk patients. Trial registration: Clinical trial.gov (NCT02134249).

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus